Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» EntreMed Raises Additional $3 Million to Further Support Clinical Development of ENMD-2076 in Ovarian Cancer
EntreMed Raises Additional $3 Million to Further Support Clinical Development of ENMD-2076 in Ovarian Cancer
EntreMed Raises Additional $3 Million to Further Support Clinical Development of ENMD-2076 in Ovarian Cancer
Submitted by
admin
on April 17, 2010 - 12:20pm
Source:
Yahoo/PR NewsWire
News Tags:
EntreMed
ENMD-2076
Aurora A/angiogenic kinase inhibitor
ovarian cancer
Headline:
EntreMed Raises Additional $3 Million to Further Support Clinical Development of ENMD-2076 in Ovarian Cancer
Do Not Allow Advertisers to Use My Personal information
